Company intelligence / Profile preview

Zafgen, Inc.

Cambridge, Massachusetts, United Statesinvestors.larimartx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Zafgen merged with Chondrial Therapeutics in May 2020 to form Larimar Therapeutics. Prior to the merger, Zafgen was developing ZGN-1061, a MetAP2 inhibitor for obesity that was on clinical hold. After the merger, the combined company focused on CTI-1601, a recombinant fusion protein for Friedreich's ataxia that had entered Phase 1 clinical trials.

Therapeutic areas: EndocrinologyRare DiseasesNeurology
Modalities: MetAP2 inhibitorsprotein replacement therapies
Industry: Biotech

Drug pipeline

1 asset

ZGN-433

Phase 1

Indications: Obesity, Severe obesity

Beyond the preview

Go deeper on Zafgen, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zafgen, Inc..

Explore the full profile